28 November 2023
SHARE NOW
Allogeneic
ATE
Cell Therapy
Raw Materials
David Sourdive joins us in this interview filmed at Advanced Therapies Europe 2023 discussing allogeneic therapies.
In this interview, David Sourdive, Executive Vice President CMC & Manufacturing at Cellectis explores the potential and challenges of allogeneic therapies as part or revolutionizing regenerative medicines. David also talks about the advantages of donor-derived therapies that pertain to manufacturing therapies.
This interview was recorded at Advanced Therapies Europe 2023.
More like this
Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing
Are you looking for a cost-effective, high-productivity extracellular vesicle (EV) production platform that overcomes traditional manufacturing challenges? Join us to discover how Univercells Technologies’ scalable fixed-bed design is transforming EV manufacturing.
14 May 2024
Women in Advanced Therapies Global 2024, Virtual Event
Experience Women in Advanced Therapies Global, a 24-hour online event uniting the community in celebration of inspiration, innovation, and empowerment. Access exclusive insights, workshops, and networking opportunities from anywhere.
8 April 2024
